Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH176 crossover trial in adults with m.3243A>G mitochondrial disease
NL-OMON42839Phase 2Recruiting
- Sponsor
- Khondrion
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonlicromanol in Mitochondriopathy, mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness (MIDD) (2 arms), sponsored by Khondrion. Primary endpoint: Change from baseline in gait parameters. Started Sep 2016; status: recruiting.
02
Drugs
sonlicromanol
03
Conditions
Mitochondriopathymitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)maternally inherited diabetes and deafness (MIDD)
Beyond the preview
Go deeper on NL-OMON42839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42839.